Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitro.
Dermal absorption
Franz cell
Human skin
In vitro permeation testing
Reconstructed human epidermis
Strat-M
Journal
Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
12
01
2023
revised:
24
05
2023
accepted:
09
06
2023
pmc-release:
01
09
2024
medline:
14
7
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Skin permeation is a primary consideration in the safety assessment of cosmetic ingredients, topical drugs, and human users handling veterinary medicinal products. While excised human skin (EHS) remains the 'gold standard' for in vitro permeation testing (IVPT) studies, unreliable supply and high cost motivate the search for alternative skin barrier models. In this study, a standardized dermal absorption testing protocol was developed to evaluate the suitability of alternative skin barrier models to predict skin absorption in humans. Under this protocol, side-by-side assessments of a commercially available reconstructed human epidermis (RhE) model (EpiDerm-200-X, MatTek), a synthetic barrier membrane (Strat-M, Sigma-Aldrich), and EHS were performed. The skin barrier models were mounted on Franz diffusion cells and the permeation of caffeine, salicylic acid, and testosterone was quantified. Transepidermal water loss (TEWL) and histology of the biological models were also compared. EpiDerm-200-X exhibited native human epidermis-like morphology, including a characteristic stratum corneum, but had an elevated TEWL as compared to EHS. The mean 6 h cumulative permeation of a finite dose (6 nmol/cm
Identifiants
pubmed: 37315744
pii: S0887-2333(23)00079-6
doi: 10.1016/j.tiv.2023.105630
pmc: PMC10527924
mid: NIHMS1911777
pii:
doi:
Substances chimiques
Caffeine
3G6A5W338E
Salicylic Acid
O414PZ4LPZ
Testosterone
3XMK78S47O
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105630Subventions
Organisme : Intramural FDA HHS
ID : FD999999
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6888-92
pubmed: 2395883
Eur J Pharm Sci. 2015 Jan 25;67:113-118
pubmed: 25447745
Altern Lab Anim. 2008 May;36(2):161-87
pubmed: 18522484
J Appl Toxicol. 2020 Mar;40(3):403-415
pubmed: 31867769
Toxicol In Vitro. 2020 Dec;69:104990
pubmed: 32882340
Int Immunol. 2015 Jun;27(6):269-80
pubmed: 25813515
AAPS J. 2013 Jan;15(1):41-52
pubmed: 23054971
Clin Pharmacokinet. 2015 Nov;54(11):1095-106
pubmed: 26063051
Biochim Biophys Acta. 2006 Dec;1758(12):2080-95
pubmed: 16945325
J Invest Dermatol. 1972 Mar;58(3):114-23
pubmed: 4622425
J Pharm Sci. 2012 Jul;101(7):2584-95
pubmed: 22517028
Skin Pharmacol Appl Skin Physiol. 2002;15 Suppl 1:31-9
pubmed: 12476007
Clin Pharmacol. 2016 Oct 19;8:163-176
pubmed: 27799831
Toxicol Sci. 2022 Jul 28;188(2):143-152
pubmed: 35689632
J Control Release. 2003 Jan 9;86(1):69-92
pubmed: 12490374
J Invest Dermatol. 1976 Oct;67(4):518-20
pubmed: 823268
Clin Exp Pharmacol Physiol. 1997 Nov;24(11):874-9
pubmed: 9363373
Arch Dermatol. 1975 Jun;111(6):740-3
pubmed: 1094962
Skin Pharmacol Physiol. 2011;24(4):224-30
pubmed: 21455015
Int J Pharm. 2001 Mar 14;215(1-2):51-6
pubmed: 11250091
J Am Assoc Lab Anim Sci. 2015 Mar;54(2):214-23
pubmed: 25836969
Toxicol In Vitro. 2018 Sep;51:129-135
pubmed: 29698667
Int J Pharm. 2018 Aug 25;547(1-2):432-437
pubmed: 29890259
EFSA J. 2017 Jun 30;15(6):e04873
pubmed: 32625532
Altern Lab Anim. 2006 Jun;34(3):283-94
pubmed: 16831060
Tissue Eng Part C Methods. 2019 Jun;25(6):334-343
pubmed: 31007132
Toxicol In Vitro. 2005 Sep;19(6):813-22
pubmed: 15913948
Exp Dermatol. 2014 Jun;23(6):441-3
pubmed: 24758415
Int J Pharm. 2009 Jun 22;375(1-2):41-7
pubmed: 19481689
Curr Probl Dermatol. 2016;49:8-26
pubmed: 26844894
J Invest Dermatol. 1975 Mar;64(3):190-5
pubmed: 123263
Respir Res. 2015 Feb 21;16:30
pubmed: 25851441
Eur J Pharm Sci. 2012 Apr 11;45(5):698-707
pubmed: 22326705
Curr Protoc Pharmacol. 2020 Dec;91(1):e79
pubmed: 32991075